NEW YORK, Feb. 24, 2026 /PRNewswire/ — AEYE Health, the leader in ophthalmic AI and retinal diagnostics and the developer of AEYE-DS, the fastest growing solution for diabetic eye exams in the U.S., today announced the publication of a landmark study in BMJ Innovations.
Recor Medical is gaining reimbursement in Japan’s healthcare system for its Paradise renal denervation for treating hypertension, enabling it to better compete with Medtronic’s rival Symplicity Spyral system.
Olympus announced today that it received FDA clearance for pediatric use for two of the single-use bronchoscopes it distributes in the U.S.
BOSTON, Feb. 23, 2026 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represents the next generation of Haemonetics’ proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation.
ATLANTA, Feb. 23, 2026 /PRNewswire/ — MiRus® today announced FDA 510(k) clearance and commercial launch of the IO™ Expandable Wedge Osteotomy System, an innovative solution designed to bring intraoperative precision and adjustability to foot and ankle osteotomy procedures.
Medtronic (NYSE: MDT)+ announced today that it received CE mark for its ColonPRO fourth-generation software for AI-assisted colonoscopy.
Biotronik announced today that it received FDA approval for its Solia CSP S pacing lead for left bundle branch area pacing (LBBAP).
Allurion Technologies (NYSE:ALUR) announced today that the FDA granted premarket approval (PMA) for its Allurion Gastric Balloon System.
Medtronic is investing in the rollout of the Symplicity Spyral renal denervation procedure, including hiring for new market development roles, CEO Geoff Martha said on an earnings call.
Medtronic continues to expand the growth opportunities for its hypertension-treating Symplicity Spyral renal denervation system.